Industry News (Clinical Trials)

Second SU101 Trial for Cancer Patients Begins

Published in Cancer Weekly, October 9th, 1995

Sugen, Inc., Redwood City, California, announced its second clinical trial with SU101 has been initiated at the Cancer Therapy and Research Center (CTRC) of the University of Texas Health Science Center in San Antonio.

Under a Phase I clinical trial protocol, Sugen is testing the safety and pharmacokinetics and looking for antitumor activity of multiple doses of SU101 in patients with solid tumors.

"Early animal studies of SU101 have demonstrated potential in treating a number of malignancies in patients with reduced side effects," explained Daniel Von Hoff, Director of the Institute for Drug Development of CTRC. "With the current trial, CTRC will...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-10-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry